Immunometabolism company Sitryx debuts with GSK ties, $30M

Sitryx Therapeutics Ltd. (Oxford, U.K.) emerged from stealth on Oct. 8 with $30 million from a series A round to develop disease-modifying therapeutics for immuno-oncology and immuno-inflammation, which CEO Neil Weir expects to be enough runway to submit an IND and/or clinical trial application for one program and initiate IND-enabling studies for a second.

The round was co-led by seed investor SV Health Investors and new investor Sofinnova Partners, with participation from Longwood Fund and GlaxoSmithKline plc (LSE:GSK; NYSE:GSK)...